We performed a secondary analysis of the Bumetanide for Developmental Disorders (BUDDI;EUDRA-CT-2020-002196-35) trial to examine whether baseline neurocognitive profiles are associated with differential behavioral and cognitive treatment response. Participants (7-19 years) with atypical sensory reactivity and ASD, ADHD, epilepsy, or TSC diagnoses received 6-months of bumetanide treatment (max 3.0 mg/day) within a multiple-baseline SCED. Neurocognitive functioning was assessed across multiple…
